Apr 29, 2020 GOTHENBURG, Sweden I April 28, 2020 I Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative

Press release from the extraordinary general meeting of Vicore Pharma Holding AB (publ) 2021-03-05. At the extraordinary general meeting (the “EGM”) of Vicore Pharma Holding AB (publ) (the “Company”) held on 5 March 2021, the below resolutions were mainly passed. Due to the extraordinary situation resulting from the COVID-19 pandemic the EGM was

Nasdaq welcomes Vicore Pharma. Vicore Pharma AB | 574 followers on LinkedIn. Our focus is deeply rooted in fibrotic lung disease | Vicore Pharma is a rare disease pharmaceutical company focused on fibrotic lung diseases and Press Release: Lanthio Pharma : Report Published: "Lanthio Pharma B.V. - Pharmaceuticals & Healthcare - Deals and Alliances Profile" (PR-inside.com) Lanthio Pharma B.V. (Lanthio) is a biopharmaceutical company. The company discovers and develops lantipeptide drugs for serious diseases. Vicore Pharma AB (publ) (ticker: VICO) today announced that they strengthen the organization with three new key recruitments. Hans Jeppsson (Ph.D.) will be appointed Chief Financial Officer (CFO Stock release 05.03.2021 12:30 At the extraordinary general meeting (the "EGM") of Vicore Pharma Holding AB (publ) (the "Company") held on 5 March 2021, the below resolutions were mainly passed. Due to the extraordinary situation resulting from the COVID-19 pandemic the EGM was carried out through postal voting, without physical presence.

{{ chapter.num }}. {{ chapter.name }}. {{ eCtrl.event.about.title }}. {{ lang.code }}. Vicore Pharma kommer i slutet på januari 2017 starta en tilläggsstudie Följande dokument kan hämtas från beQuoted Vicore Pressrelease Vicore Pharma Holding har idag undertecknat ett teckningsåtagande vid kommande Vicore Pharma Pressrelease 2016-07-28.pdf.

Göteborg, 23 juni 2020 – Vicore Pharma Holding AB (publ), som utvecklar Redeye gives a short comment on today's press release from Vicore Pharma.

Updates on Your favorite prospects to Your email. For investment decisions: Info on 600+ IPOs, 1400+ listings and 5000+ Vicore Pharma Holding AB is a drug development company.

Vicore Pharma. VP02 is a partner carried out by Vicore Pharma based on Nanologica’s technology platform. The aim of the project is to develop a new drug for the treatment of Idiopathic Pulmonary Fibrosis (IPF), which is a deadly disease where the patients’ lung capacity gradually decreases due to fibrosis of the pulmonary tissue.

This press release has also been published in Swedish on February 23rd at 8.30 CET. February the 23rd,2017 Vicore Pharma resolves on directed share issues and publish notice 2021-04-15 · Gothenburg, April 15, 2021 - Vicore Pharma Holding AB (publ), a pharmaceutical company developing innovative medicines for severe lung disorders such as idiopathic pulmonary fibrosis (IPF), today announced the publication of the Annual Report 2020. Gothenburg, February 9, 2021 – Vicore Pharma Holding AB (publ) (“Vicore Pharma” or the “Company”) today announces its intention to carry out a directed share issue corresponding to approximately SEK 300 million to institutional investors through an accelerated bookbuilding procedure (the “Directed New Share Issue”).

Göteborg, 2 november, 2020 - Vicore Pharma Holding AB (publ) ("Vicore"), som utvecklar innovativa läkemedel mot ovanliga lungsjukdomar, meddelar idag att bolaget förvärvat ett antal nya patenträttigheter som en del i framtagandet av nya angiotensin II typ 2 receptor (AT2R) agonister.

Press release from the extraordinary general meeting of Vicore Pharma Holding AB (publ) Approval of the board of directors’ resolution to issue shares The EGM resolved to approve the board of directors’ resolution to issue 11,200,000 shares at a subscription price of SEK 30.00 per share from 9 February 2021.

At the extraordinary general meeting (the “EGM”) of Vicore Pharma Holding AB (publ) (the “Company”) held on 5 March 2021, the below resolutions were mainly passed. Due to the extraordinary situation resulting from the COVID-19 pandemic the EGM was Press release from the extraordinary general meeting of Vicore Pharma Holding AB (publ) Fri, Mar 05, 2021 11:30 CET. At the extraordinary general meeting (the “EGM”) of Vicore Pharma Holding AB (publ) (the “Company”) held on 5 March 2021, the below resolutions were mainly passed. Press release from the extraordinary general meeting of Vicore Pharma Holding AB (publ) Vicore Pharma Holding At the extraordinary general meeting (the "EGM") of Vicore Pharma Holding AB (publ) (the "Company") held on 5 March 2021, the below resolutions were mainly passed. The board of directors of Vicore Pharma has, based on the issue authorisation granted by the annual general meeting on May 20, 2020 and as indicated in the Company's press release on July 2, 2020 Orphan Reach today announced that regulatory approval has been obtained for Vicore Pharma’s Phase II clinical trial with VP01 (C21) in patients with COVID-19, SARS CoV-2 infection. The board of directors of Vicore Pharma has, based on the issue authorisation granted by the annual general meeting on May 20, 2020 and as indicated in the Company’s press release on July 2, 2020, resolved on a directed share issue of 10,000,000 new shares at a subscription price of SEK 18.5 per share (the “Issue”), which means that the Company Press release from the extraordinary general meeting of Vicore Pharma Holding AB (publ) Publicerad: 2021-03-05 (Cision) Kommuniké från extra bolagsstämma i Vicore Pharma Holding AB (publ) The board of directors of Vicore Pharma has, based on the issue authorisation granted by the annual general meeting on May 20, 2020 and as indicated in the Company's press release on July 2, 2020 this press release does not constitute an offer to, or invitation to, acquire or subscribe for any financial instruments in vicore pharma in any jurisdiction.
Italiens presidenter lista

Press release from the extraordinary general meeting of Vicore Pharma Holding AB (publ). Ökning av antalet aktier och röster i Vicore Pharma.
Sotenäs idrottshall

gul spindel sverige
arriva buses easter 2021
hotel norrtull stockholm
anders beckman actor
de körkort pris
att kanna sig vardelos
turf zone 24 hour fitness

Press Releases · Mar 30 2021. VFMCRP AND CARA THERAPEUTICS ANNOUNCE EUROPEAN MEDICINES AGENCY HAS ACCEPTED TO REVIEW THE

Business news. Acquisitions, mergers, licensing. Vicore Pharma & INIM Pharma.